XTL Biopharmaceuticals Overview
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has three product candidates in clinical development. XTLs hCDR1 peptide is a compound that works via a novel mechanism for the treatment of systemic lupus erythematosus (SLE). hCDR1 has completed three clinical trials involving more than 400 patients. Recombinant erythropoietin is a compound being developed by XTL with the potential to help advanced-stage multiple myeloma patients live longer with a better quality of life. The companys SAM-101 is a proprietary combination of antipsychotic drugs and a known medicinal compound for the treatment of psychotic diseases, with a focus on schizophrenia. SAM-101 has completed a phase 2a study in accordance with the Helsinki guidelines at the Shalvata Medical Center.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
XTL Names Mr. Noam Band as its New Chief Executive Officer
XTL Biopharmaceuticals Ltd. has appointed Noam Band as its new Chief Executive Officer, succeeding Shlomo Shalev, who will continue as Chairman of the Board. Mr. Band brings extensive experience in strategic business development and operational leadership, having previously held executive roles in various technology and digital marketing companies. The company, which holds a 100% share in The Social Proxy Ltd., a web data AI company, is focused on innovation and operational excellence. The appointment is seen as a positive step towards growth and expansion, with a focus on leveraging AI technology for business intelligence applications. The company also holds an IP portfolio for the treatment of Lupus disease.
Management Changes
growth-positive
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
XTL Biopharmaceuticals Ltd. announced the acquisition of THE SOCIAL PROXY Ltd., an AI web data company. The acquisition was completed through a private placement, with XTL acquiring all of the issued and outstanding share capital of Social Proxy. The deal also included the issuance of additional warrants to the shareholders of Social Proxy. The acquisition is part of XTLs strategy to expand its assets portfolio with high potential assets. To support the growth of Social Proxy and the companys financial needs, XTL also completed an investment of US$1,500,000 through a private placement.
AcquisitionInvestment
growth-positive
XTL Entered Definitive Agreement to Acquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced its acquisition of THE SOCIAL PROXY Ltd., an AI web data company. The acquisition is part of XTLs strategy to expand its assets portfolio with high potential assets. The company will acquire all of the issued and outstanding share capital of Social Proxy in exchange for the issuance of ADSs of the company and a payment of US$430,000 to the shareholders of Social Proxy. In addition, XTL has secured a commitment of an investment amount of US$1,500,000 through a private placement to support the company’s financial needs and complete the transaction.
AcquisitionInvestment
growth-positive
XTL To Aquire The Social Proxy
XTL Biopharmaceuticals Ltd. has announced its plans to acquire THE SOCIAL PROXY Ltd., a web data AI company. The acquisition will be made in exchange for the issuance of ADSs of the Company and a payment of US$430,000 to the shareholders of Social Proxy. As part of the transaction, XTL has secured a commitment of an investment of US$1,500,000 through a private placement. The investment is conditioned upon obtaining shareholders’ approval as Mr. Alexander Rabinovich, a shareholder and a director of the Company, is one of the investors in this Private Placement. The completion of the transaction is subject to various conditions.
AcquisitionInvestment
growth-positive
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
XTL Biopharmaceuticals Ltd., a clinical stage biopharmaceutical company based in Israel, has confirmed that its operations remain unaffected by the recent terrorist attacks and subsequent declaration of war by the Israeli government against Hamas. The company, which focuses on treatments for systemic lupus erythematosus and Sjögren’s syndrome, continues to operate normally and is exploring collaborations with strategic partners for further clinical trials. Additionally, XTL is looking to expand its portfolio by identifying new assets. The companys headquarters are located near Tel Aviv, away from conflict zones, ensuring business continuity. XTL is publicly traded on the Nasdaq and Tel Aviv Stock Exchange.
PartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30.04M |
| Last funding | $1.5M |
| Stage | Public |
| Rounds | 6 |
| Investors | 8 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | xtlbio.com/ |
Locations
HaHaroshet St 5, Ra'anana, Israel
Photos & Videos
1 item(s)
